VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Concepcion on the AUA PSA Screening Guidelines

Raoul S. Concepcion, MD
Published: Thursday, May 09, 2013

Raoul S. Concepcion, MD, the Director of Clinical Research and a Urologic Surgeon at Urology Associates, PC, in Nashville, Tennessee, discusses the new guidelines on prostate cancer screening that were issued by the American Urological Association (AUA).

These guidelines are largely in response to recommendations made by the US Preventive Services Task Force (USPSTF) against PSA screening. Concepcion expects these guidelines to be controversial, since they seem to contradict the USPSTF.

The overarching theme, Concepcion believes, is a need for transparency with patients. The new guidelines are more individualized, stressing the importance of discussing options with patients. Moreover, Concepcion notes, it remains important to ensure that high-risk patients are aware of early detection programs.

<<< View more from the 2013 AUA Annual Meeting

Raoul S. Concepcion, MD, the Director of Clinical Research and a Urologic Surgeon at Urology Associates, PC, in Nashville, Tennessee, discusses the new guidelines on prostate cancer screening that were issued by the American Urological Association (AUA).

These guidelines are largely in response to recommendations made by the US Preventive Services Task Force (USPSTF) against PSA screening. Concepcion expects these guidelines to be controversial, since they seem to contradict the USPSTF.

The overarching theme, Concepcion believes, is a need for transparency with patients. The new guidelines are more individualized, stressing the importance of discussing options with patients. Moreover, Concepcion notes, it remains important to ensure that high-risk patients are aware of early detection programs.

<<< View more from the 2013 AUA Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x